Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas. - Lake KE; Jackson M; Hull S; All S; Patel AM; Li X; Desai NB; Yilmaz E; Wolfe H; Zahid MF; Li HC; Awan F; et al. (Frontiers in oncology, 2025)